Abbvie Inc

NYSE: ABBV
$193.46
-$0.16 (-0.1%)
Closing Price on September 20, 2024

ABBV Articles

Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
AbbVie released a better-than-expected quarterly report early on Friday, but shares retreated afterward.
The July 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger health care companies that are about to report their quarterly results.
Four pharmaceutical industry leaders are poised to report second-quarter results next week, and one key analyst sees the relatively good print from Johnson & Johnson as a good signal for the...
The top analyst upgrades, downgrades and other research calls from Thursday include AbbVie, Amazon.com, Anadarko, Broadcom, Chipotle Mexican Grill, ConocoPhiilips, General Electric, Honeywell,...
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
AbbVie shares dipped on Wednesday after the company gave a less than impressive update from its late-stage lymphoma trial.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in July.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Analysts at Jefferies have come up with a list of four pharmaceuticals stocks that may be good investments for a time of uncertainty in global markets.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Dana, Humana, International Paper, Navistar, Southwest Airlines and Tesla.